DOCSLIB.ORG

Northern Ireland Prescription Code Book Drugs Section September 2021

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Northern Ireland Prescription Code Book Drugs Section September 2021 Family Practitioner Services, Pharmaceutical Services, 2 Franklin Street, Belfast BT2 8DQ Telephone No. 028 9053 5613, Fax No. 028 9053 2963 Northern Ireland Prescription Code Book Drugs section September 2021 Page 1 of 587 Effective for prescriptions dispensed September 2021 BSO Code dm+d Pack Description Code Number Special ZD Of Container 38960 4SURE beta-ketone testing strips 4S-810-4183401-001 (Nipro Diagnostics (UK) Ltd) 10 strip strips 38961 4SURE testing strips (Nipro Diagnostics (UK) Ltd) 50 strip strips 4144 AAA 1.5mg/dose sore throat spray (Manx Healthcare Ltd) 60 dose [BSO pack = 1] BSO Unit Of Measure Code No. devices dispensed 70598 (DT) Abacavir 600mg / Lamivudine 300mg tablets 30 tablet tablets 9154 Abasaglar 100units/ml solution for injection 3ml cartridges (Eli Lilly and Company Ltd) 5 cartridge cartridges ZD 9038 Abasaglar KwikPen 100units/ml solution for injection 3ml pre-filled pens (Eli Lilly and Company Ltd) 5 pre- injections ZD filled disposable injection 70088 (DT) Abatacept 125mg/1ml solution for injection pre-filled disposable devices 4 pre-filled disposable injections ZD injection 70089 (DT) Abatacept 125mg/1ml solution for injection pre-filled syringes 4 pre-filled disposable injection injections ZD 70144 Abelcet 100mg/20ml concentrate for suspension for infusion vials (Teva UK Ltd) 10 vial vials Hospital Only 3303 Abidec Multivitamin drops (Omega Pharma Ltd) 25 ml mls 4043 Abilify 10mg orodispersible tablets (Otsuka Pharmaceuticals (U.K.) Ltd) 28 tablet 4 x 7 tablets tablets 3006 Abilify 10mg tablets (Otsuka Pharmaceuticals (U.K.) Ltd) 28 tablet 4 x 7 tablets tablets 4056 Abilify 15mg orodispersible tablets (Otsuka Pharmaceuticals (U.K.) Ltd) 28 tablet 4 x 7 tablets tablets 3015 Abilify 15mg tablets (Otsuka Pharmaceuticals (U.K.) Ltd) 28 tablet 4 x 7 tablets tablets 3971 Abilify 1mg/ml oral solution (Otsuka Pharmaceuticals (U.K.) Ltd) 150 ml mls 3023 Abilify 30mg tablets (Otsuka Pharmaceuticals (U.K.) Ltd) 28 tablet 4 x 7 tablets tablets Page 2 of 587 Effective for prescriptions dispensed September 2021 BSO Code dm+d Pack Description Code Number Special ZD Of Container 2991 Abilify 5mg tablets (Otsuka Pharmaceuticals (U.K.) Ltd) 28 tablet 4 x 7 tablets tablets 3217 Abilify 9.75mg/1.3ml solution for injection vials (Otsuka Pharmaceuticals (U.K.) Ltd) 1 vial vials 10537 Abilify Maintena 400mg powder and solvent for prolonged-release suspension for injection pre-filled injections ZD syringes (Otsuka Pharmaceuticals (U.K.) Ltd) 1 pre-filled disposable injection 10538 Abilify Maintena 400mg powder and solvent for prolonged-release suspension for injection vials (Otsuka vials ZD Pharmaceuticals (U.K.) Ltd) 1 vial 5841 Abstral 100microgram sublingual tablets (Kyowa Kirin Ltd) 10 tablet tablets ZD 5984 Abstral 100microgram sublingual tablets (Kyowa Kirin Ltd) 30 tablet 3 x 10 tablets tablets ZD 5854 Abstral 200microgram sublingual tablets (Kyowa Kirin Ltd) 10 tablet tablets ZD 5853 Abstral 200microgram sublingual tablets (Kyowa Kirin Ltd) 30 tablet 3 x 10 tablets tablets ZD 5850 Abstral 300microgram sublingual tablets (Kyowa Kirin Ltd) 10 tablet tablets ZD 5849 Abstral 300microgram sublingual tablets (Kyowa Kirin Ltd) 30 tablet 3 x 10 tablets tablets ZD 5848 Abstral 400microgram sublingual tablets (Kyowa Kirin Ltd) 10 tablet tablets ZD 5844 Abstral 400microgram sublingual tablets (Kyowa Kirin Ltd) 30 tablet 3 x 10 tablets tablets ZD 5856 Abstral 600microgram sublingual tablets (Kyowa Kirin Ltd) 30 tablet 3 x 10 tablets tablets ZD 5842 Abstral 800microgram sublingual tablets (Kyowa Kirin Ltd) 30 tablet 3 x 10 tablets tablets ZD 33487 Abtard 15mg modified-release tablets (Ethypharm UK Ltd) 56 tablet 4 x 14 tablets tablets ZD 33489 Abtard 30mg modified-release tablets (Ethypharm UK Ltd) 56 tablet 4 x 14 tablets tablets ZD 33490 Abtard 40mg modified-release tablets (Ethypharm UK Ltd) 56 tablet 4 x 14 tablets tablets ZD Page 3 of 587 Effective for prescriptions dispensed September 2021 BSO Code dm+d Pack Description Code Number Special ZD Of Container 33492 Abtard 60mg modified-release tablets (Ethypharm UK Ltd) 56 tablet 4 x 14 tablets tablets ZD 33493 Abtard 80mg modified-release tablets (Ethypharm UK Ltd) 56 tablet 4 x 14 tablets tablets ZD 14163 (DT) Acacia spray dried powder 250 gram grams 14144 (DT) Acamprosate 333mg gastro-resistant tablets 168 tablet tablets 13402 (DT) Acarbose 100mg tablets 90 tablet tablets 13401 (DT) Acarbose 50mg tablets 90 tablet tablets 37305 Accrete D3 One a Day 1000mg/880unit chewable tablets (Thornton & Ross Ltd) 30 tablet tablets 10539 Accrete D3 tablets (Thornton & Ross Ltd) 60 tablet 6 x 10 tablets tablets 3846 Accupro 10mg tablets (Pfizer Ltd) 28 tablet 4 x 7 tablets tablets 3874 Accupro 20mg tablets (Pfizer Ltd) 28 tablet 4 x 7 tablets tablets 7390 Accupro 40mg tablets (Pfizer Ltd) 28 tablet 4 x 7 tablets tablets 3827 Accupro 5mg tablets (Pfizer Ltd) 28 tablet 4 x 7 tablets tablets 7113 Accuretic 10mg/12.5mg tablets (Pfizer Ltd) 28 tablet 4 x 7 tablets tablets 10540 Acea 0.75% gel (Ferndale Pharmaceuticals Ltd) 40 gram grams 12715 (DT) Acebutolol 100mg capsules 84 capsule capsules 12716 (DT) Acebutolol 200mg capsules 56 capsule capsules 12717 (DT) Acebutolol 400mg tablets 28 tablet tablets 13714 (DT) Aceclofenac 100mg tablets 60 tablet tablets 71586 AceNAC 600mg tablets (Essential-Healthcare Ltd) 30 tablet tablets Page 4 of 587 Effective for prescriptions dispensed September 2021 BSO Code dm+d Pack Description Code Number Special ZD Of Container 12856 (DT) Acenocoumarol 1mg tablets 100 tablet tablets 12384 (DT) Acetazolamide 250mg modified-release capsules 30 capsule capsules 12385 (DT) Acetazolamide 250mg tablets 112 tablet tablets 37778 Aceteff 600mg effervescent tablets (Dunelm Pharmaceuticals Ltd) 30 tablet 2 x 15 tablets tablets (2 x 15) 13694 (DT) Acetic acid 2% ear spray 5 ml [BSO pack = 1] BSO Unit Of Measure Code No. devices dispensed 13738 (DT) Acetone liquid 50 ml mls ZD 36627 (DT) Acetylcysteine 200mg oral powder sachets sugar free 30 sachet sachets 37560 (DT) Acetylcysteine 2g/10ml solution for infusion ampoules 10 ampoule ampoules 14661 (DT) Acetylcysteine 5% eye drops 10 ml mls 18788 (DT) Acetylcysteine 600mg capsules 30 capsule capsules 37673 (DT) Acetylcysteine 600mg effervescent tablets sugar free 30 tablet tablets (2 x 15) 37779 Acetyl-NAC 200mg oral powder sachets sugar free (TriOn Pharma Ltd) 30 sachet 2 x 15 sachets sachets 37780 Acetyl-NAC 600mg capsules (TriOn Pharma Ltd) 30 capsule capsules 37781 Acetyl-NAC 600mg tablets (TriOn Pharma Ltd) 30 tablet tablets 678 (DT) Aciclovir 200mg dispersible tablets 25 tablet tablets 239 (DT) Aciclovir 200mg tablets 25 tablet tablets 12473 (DT) Aciclovir 200mg/5ml oral suspension sugar free 125 ml mls Page 5 of 587 Effective for prescriptions dispensed September 2021 BSO Code dm+d Pack Description Code Number Special ZD Of Container 12479 (DT) Aciclovir 3% eye ointment 4.5 gram BSO Unit Of Measure Decimal Quantity: code each pack as 5 681 (DT) Aciclovir 400mg dispersible tablets 56 tablet tablets 241 (DT) Aciclovir 400mg tablets 56 tablet tablets 12482 (DT) Aciclovir 400mg/5ml oral suspension sugar free 100 ml mls 5648 (DT) Aciclovir 5% cream 10 gram grams 601 (DT) Aciclovir 5% cream 2 gram grams 698 (DT) Aciclovir 800mg dispersible tablets 35 tablet tablets 250 (DT) Aciclovir 800mg tablets 35 tablet tablets 33494 Acidex Advance oral suspension aniseed (Wockhardt UK Ltd) 250 ml mls 33495 Acidex Advance oral suspension aniseed (Wockhardt UK Ltd) 500 ml mls 33496 Acidex Advance oral suspension peppermint (Wockhardt UK Ltd) 250 ml mls 33497 Acidex Advance oral suspension peppermint (Wockhardt UK Ltd) 500 ml mls 20298 Acidex oral suspension aniseed (Pinewood Healthcare) 500 ml mls 37782 Acidex oral suspension peppermint (Pinewood Healthcare) 150 ml mls 10541 Acidex oral suspension peppermint (Pinewood Healthcare) 500 ml mls 10542 Acidophilus Extra 10 capsules (Lamberts Healthcare Ltd) 30 capsule capsules 10543 Acidophilus Extra 10 capsules (Lamberts Healthcare Ltd) 60 capsule capsules Page 6 of 587 Effective for prescriptions dispensed September 2021 BSO Code dm+d Pack Description Code Number Special ZD Of Container 10544 Acidophilus Extra 4 capsules (Lamberts Healthcare Ltd) 30 capsule capsules 10545 Acidophilus Extra 4 capsules (Lamberts Healthcare Ltd) 60 capsule capsules 10546 Aciferol D3 1,000unit tablets (Rhodes Pharma Ltd) 90 tablet tablets 33498 Aciferol D3 10,000unit tablets (Rhodes Pharma Ltd) 30 tablet tablets 10547 Aciferol D3 2,000units/ml liquid (Rhodes Pharma Ltd) 100 ml mls 37783 Aciferol D3 2,200unit tablets (Rhodes Pharma Ltd) 90 tablet tablets 33499 Aciferol D3 20,000unit tablets (Rhodes Pharma Ltd) 30 tablet tablets 10548 Aciferol D3 3,000unit tablets (Rhodes Pharma Ltd) 60 tablet tablets 10549 Aciferol D3 3,000units/ml liquid (Rhodes Pharma Ltd) 100 ml mls 33500 Aciferol D3 30,000unit capsules (Rhodes Pharma Ltd) 10 capsule capsules 10550 Aciferol D3 400unit tablets (Rhodes Pharma Ltd) 90 tablet tablets 33501 Aciferol D3 5,000unit tablets (Rhodes Pharma Ltd) 60 tablet tablets 33502 Aciferol D3 50,000unit capsules (Rhodes Pharma Ltd) 10 capsule capsules 13576 (DT) Acipimox 250mg capsules 90 capsule capsules 14583 (DT) Acitretin 10mg capsules 60 capsule capsules 14584 (DT) Acitretin 25mg capsules 60 capsule capsules 70180 Aclasta 5mg/100ml infusion bottles (Novartis Pharmaceuticals UK Ltd) 1 bottle bottles ZD 14914 (DT) Aclidinium bromide 375micrograms/dose dry powder inhaler 60 dose doses Page 7 of 587 Effective for prescriptions dispensed September 2021 BSO Code dm+d Pack Description Code
Load more

Recommended publications
  • Consumer Superbrands 2019 Top 10 Consumer Superbrands Relevancy
    Consumer Superbrands 2019 Top 10 Consumer Superbrands BRAND CATEGORY LEGO 1 Child Products - Toys and Education Apple 2 Technology - General Gillette 3 Toiletries - Men's Grooming Rolex 4 Watches British Airways 5 Travel - Airlines Coca-Cola 6 Drinks - Non-Alcoholic - Carbonated Soft Drinks Andrex 7 Household - Kitchen Rolls, Toilet Roll and Tissues Mastercard 8 Financial - General Visa 9 Financial - General Dyson 10 Household & Personal Care Appliances Relevancy Index Top 20 BRAND CATEGORY Amazon 1 Retail - Entertainment & Gifts Aldi 2 Retail - Food & Drink Macmillan Cancer Support 3 Charities Netflix 4 Media - TV Google 5 Social, Search & Comparison Sites Lidl 6 Retail - Food & Drink PayPal 7 Financial - General LEGO 8 Child Products - Toys and Education Samsung 9 Technology - General YouTube 10 Social, Search & Comparison Sites Visa 11 Financial - General Heathrow 12 Travel - Airports Purplebricks 13 Real Estate Cancer Research UK 14 Charities Oral-B 15 Toiletries - Oral Care Apple 16 Technology - General Dyson 17 Household & Personal Care Appliances TripAdvisor 18 Travel - Agents & Tour Operators Nike 19 Sportswear & Equipment Disney 20 Child Products - Toys and Education continues... Consumer Superbrands 2019 Category Winners CATEGORY BRAND Automotive - Products Michelin Automotive - Services AA Automotive - Vehicle Manufacturer Mercedes-Benz Charities Cancer Research UK Child Products - Buggies, Seats and Cots Mamas & Papas Child Products - General JOHNSON'S Child Products - Toys and Education LEGO Drinks - Alcoholic - Beer, Ale
    [Show full text]
  • Betterbusiness Betterfinancials How We Drive Growth and Outperformance
    Reckitt Benckiser Group plc Annual Report and Financial2015 Statements betterbusiness 2015 Reckitt Benckiser Group plc (RB) Annual Report and Financial Statements We make a difference to people’s lives through a trusted portfolio of brands, across consumer health, hygiene and home. Our vision Our purpose A world where people are To make a difference, by healthier and live better. giving people innovative solutions for healthier lives and happier homes. Our strategy betterbusiness betterfinancials How we drive growth and outperformance Chief Executive’s Review on pages 8–9 bettersociety betterenvironment How we support How we reduce our communities and our environmental develop our people impact Strategic framework on pages 12–13 Contents Strategic Report bettersociety Governance Report 1 Highlights 24 – Workplace 46 Board of Directors 2 At a glance 26 – Communities 50 Executive Committee 4 Chairman’s Statement 26 – Products 52 Chairman’s Statement on 7 Reasons why RB delivers betterenvironment Corporate Governance 8 Chief Executive’s Review 27 – Greenhouse gas emissions 54 Corporate Governance Statement 10 Our unique culture 28 – Water 60 Nomination Committee Report 12 Strategic framework 28 – Waste 61 Audit Committee Report 14 Our market and resources 29 – Sourcing 66 Directors’ Remuneration Report betterfinancials 30 Our operating model 68 Our remuneration at a glance 16 – Our strategy to deliver 32 Our operating model in action 70 Annual Report on Remuneration 17 – Organisation 34 Creating stakeholder value 79 Directors’ Remuneration Policy 19 – Powermarkets 36 Financial Review 85 Report of the Directors 20 – Powerbrands 40 Strategic Risks 88 Directors’ Statement of Responsibilities 22 – Virtuous earnings model Financial Statements 89 Financial Statements Any information contained in the 2015 Annual Report and Financial Statements on the price at which shares or other securities in Reckitt Benckiser Group plc have been bought or sold in the past, or on the yield on such shares or other securities, should not be relied upon as a guide to future performance.
    [Show full text]
  • 209627Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 209627Orig1s000 MULTI-DISCIPLINE REVIEW Summary Review Office Director Cross Discipline Team Leader Review Clinical Review Non-Clinical Review Statistical Review Clinical Pharmacology Review Reviewers of Multi-Disciplinary Review and Evaluation SECTIONS OFFICE/ AUTHORED/ ACKNOWLEDGED/ DISCIPLINE REVIEWER DIVISION APPROVED Mark Seggel, Ph.D. OPQ/ONDP/DNDP2 Authored: Section 4.2 Digitally signed by Mark R. Seggel -S CMC Lead DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People, cn=Mark R. Signature: Mark R. Seggel -S Seggel -S, 0.9.2342.19200300.100.1.1=1300071539 Date: 2018.08.08 16:29:15 -04'00' Frederic Moulin, DVM, PhD OND/ODE3/DBRUP Authored: Section 5 Pharmacology/ Digitally signed by Frederic Moulin -S Toxicology DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People, Reviewer Signature: Frederic Moulin -S 0.9.2342.19200300.100.1.1=2001708658, cn=Frederic Moulin -S Date: 2018.08.08 15:26:57 -04'00' Kimberly Hatfield, PhD OND/ODE3/DBRUP Approved: Section 5 Pharmacology/ Toxicology Digitally signed by Kimberly P. Hatfield -S DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People, Team Leader Signature: Kimberly P. Hatfield -S 0.9.2342.19200300.100.1.1=1300387215, cn=Kimberly P. Hatfield -S Date: 2018.08.08 14:56:10 -04'00' Li Li, Ph.D. OCP/DCP3 Authored: Sections 6 and 17.3 Clinical Pharmacology Dig ta ly signed by Li Li S DN c=US o=U S Government ou=HHS ou=FDA ou=People Reviewer cn=Li Li S Signature: Li Li -S 0 9 2342 19200300 100 1 1=20005 08577 Date 2018 08 08 15 39 23 04'00' Doanh Tran, Ph.D.
    [Show full text]
  • Etats Rapides
    List of European Pharmacopoeia Reference Standards Effective from 2015/12/24 Order Reference Standard Batch n° Quantity Sale Information Monograph Leaflet Storage Price Code per vial Unit Y0001756 Exemestane for system suitability 1 10 mg 1 2766 Yes +5°C ± 3°C 79 ! Y0001561 Abacavir sulfate 1 20 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001552 Abacavir for peak identification 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001551 Abacavir for system suitability 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0000055 Acamprosate calcium - reference spectrum 1 n/a 1 1585 79 ! Y0000116 Acamprosate impurity A 1 50 mg 1 3-aminopropane-1-sulphonic acid 1585 Yes +5°C ± 3°C 79 ! Y0000500 Acarbose 3 100 mg 1 See leaflet ; Batch 2 is valid until 31 August 2015 2089 Yes +5°C ± 3°C 79 ! Y0000354 Acarbose for identification 1 10 mg 1 2089 Yes +5°C ± 3°C 79 ! Y0000427 Acarbose for peak identification 3 20 mg 1 Batch 2 is valid until 31 January 2015 2089 Yes +5°C ± 3°C 79 ! A0040000 Acebutolol hydrochloride 1 50 mg 1 0871 Yes +5°C ± 3°C 79 ! Y0000359 Acebutolol impurity B 2 10 mg 1 -[3-acetyl-4-[(2RS)-2-hydroxy-3-[(1-methylethyl)amino] propoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! acetamide (diacetolol) Y0000127 Acebutolol impurity C 1 20 mg 1 N-(3-acetyl-4-hydroxyphenyl)butanamide 0871 Yes +5°C ± 3°C 79 ! Y0000128 Acebutolol impurity I 2 0.004 mg 1 N-[3-acetyl-4-[(2RS)-3-(ethylamino)-2-hydroxypropoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! butanamide Y0000056 Aceclofenac - reference spectrum 1 n/a 1 1281 79 ! Y0000085 Aceclofenac impurity F 2 15 mg 1 benzyl[[[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetate
    [Show full text]
  • Minutes of PRAC Meeting on 09-12 July 2018
    6 September 2018 EMA/PRAC/576790/2018 Inspections, Human Medicines Pharmacovigilance and Committees Division Pharmacovigilance Risk Assessment Committee (PRAC) Minutes of the meeting on 09-12 July 2018 Chair: June Raine – Vice-Chair: Almath Spooner Health and safety information In accordance with the Agency’s health and safety policy, delegates were briefed on health, safety and emergency information and procedures prior to the start of the meeting. Disclaimers Some of the information contained in the minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scope listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also change during the course of the review. Additional details on some of these procedures will be published in the PRAC meeting highlights once the procedures are finalised. Of note, the minutes are a working document primarily designed for PRAC members and the work the Committee undertakes. Note on access to documents Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on- going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006, Rev. 1). 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2018.
    [Show full text]
  • Icontact Newsletter
    eckitt Benckiser (formerly Reckitt & C sioners of the R olman) Pensio i for pen n Fund No. 69, September 2017 IN THIS ISSUE ROUTINE INCREASE LETTER When Hull’s Weeping Window poppy display moved on, Derby put its best foot forward with a pavement trail leading to a IS ALSO A REASSURANCE display reaching new heights The April letter, tailored to the individual and sent to RBPA at the Old Silk Mill (see P3&9). members advising them of the annual increase in their pension, may be routine but, like the annual update newsletter, is a welcome reassurance in these uncertain economic times. Also on P3 see how Dansom The letter notes: ‘The level of maintain the century-old tradition Lane’s British Legion standard annual increase applied to your Fund of employee welfare, to use the old- came out of retirement for the pension is equal to the year-on-year fashioned but very relevant words. “Poppy for Oppy” display change in the Retail Prices Index In both business and Government, (RPI) at the 31 December prior to the pensions have become a numbers increase. The rate at 31 December game. Deficits thwart takeover 2016 was 2.5%. Therefore, with effect bids; underfunding or retirement from 1 April 2017, your Fund pension age extensions could impoverish will be increased by 2.5%. some pensioners; and it is reported ‘This is in accordance with the that the government relaxation to Fund’s Rules, which provide that the allow pensioners to cash-in early is Trustees must increase pensions in resulting in serious personal debt line with RPI, up to a maximum of 5%.’ problems.
    [Show full text]
  • Contact 77 to See the Results for the “Brand Search”That Was Published in the Last Magazine
    No. 77 April 2020 RB donated £5.5 million to help combat GDPR & Pensioner Visiting resolved Covid-19 (Coronavirus) in China As you will know, we’ve had quite a In the early stages of the outbreak, RB to the moral responsibility we feel, we time trying to review our Pensioner immediately coordinated 600,000 also have an important functional role visiting procedures and updating RMB (about £60k) worth of soap and to play in enhancing personal them in order to comply with GDPR sanitizer products to help meet the disinfection through providing and meet the standards expected by cleaning and disinfection enhanced access to products which RB. We are now very pleased, and requirements in Wuhan’s hospitals. can break the chain of infection. not a little relieved, to say that the Commenting on the outbreak, RB Simple steps such as frequent hand process is now complete. CEO Laxman Narasimhan said: “We washing will aid the many efforts the immediately mobilised our experts in Chinese government is already *** STOP PRESS *** China and beyond as soon as the putting in place to protect citizens outbreak was identified. In addition across the region.” Due to the Corona Virus, we will (Press release: www.rb.com) not be making pensioner visits, in person, at the present time. All RB’s End of Year Results for 2019 other formats of Pensioner visiting RB Chief Executive, Laxman our communities. While the recent years - phone calls, WhatsApp messaging Narasimhan commented on the results have been difficult, I believe strongly in and emails - will remain in place.
    [Show full text]
  • Other Data Relevant to an Evaluation of Carcinogenicity and Its Mechanisms
    COMBINED ESTROGEN−PROGESTOGEN CONTRACEPTIVES 143 4. Other Data Relevant to an Evaluation of Carcinogenicity and its Mechanisms 4.1 Absorption, distribution, metabolism and excretion in humans The metabolism and disposition of various formulations of oral contraceptives used in humans differ. After entering the small intestine, estrogenic and progestogenic compounds in combined oral contraceptives undergo metabolism by bacterial enzymes and enzymes in the intestinal mucosa to varying extents. The mixture of metabolized and unmetabolized compounds then undergoes intestinal absorption, and thus enters the portal vein blood, which perfuses the liver. In the liver, the compounds can be metabolized extensively, which leads to variations in the amount of active drug. A fraction of the absorbed dose of ethinyl- estradiol and some progestogens is also excreted in the bile during its first transit through the liver. Although some of these compounds are partially reabsorbed via the enterohepatic circulation, a fraction may also be excreted in this ‘first pass’, which reduces overall bio- availability. Since steroids penetrate normal skin easily, various systems have also been developed that deliver estrogens and progestogens parenterally, e.g. transdermal patches, nasal sprays, subcutaneous implants, vaginal rings and intrauterine devices (Fanchin et al., 1997; Dezarnaulds & Fraser, 2002; Meirik et al., 2003; Sarkar, 2003; Wildemeersch et al., 2003; Sturdee et al., 2004). These different modes of administration have been described previously (IARC, 1999). In general, all parenteral routes avoid loss of the drug by hepatic first-pass metabolism and minimally affect hepatic protein metabolism. The absorption rates of orally administered estrogens and progestogens are usually rapid; peak serum values are observed between 0.5 and 4 h after intake.
    [Show full text]
  • The Realization of New Medical Alternatives to Surgery for Endometriosis
    Paradigm Shift: The Realization of New Medical Alternatives to Surgery for Endometriosis Edward M. Lichten, MD* ©2016, Edward M. Lichten, MD Journal Compilation ©2016, AARM DOI 10.14200/jrm.2016.5.0099 ABSTRACT Endometriosis is one of the most destructive benign diseases of women. It is established as developing and being present in upward of 70% of adolescents who do not experience relief of menstrual pain with use of oral contraceptives and anti- inflammatory drugs. It occurs in 8%–10% of women in the United States and is most prevalent in developed countries. Symptoms of endometriosis include disabling pain, hemorrhagic uterine bleeding, and infertility. Women with disease can expect a 12% hysterectomy rate. While present medical therapy may offer relief of many symptoms, there have been no major new directions in pharmacologic therapy since leuprolide acetate was made available in 1977. Danazol remains the only alternative to GnRH agonists with proven efficacy and reasonable side effects, according to Cochrane Reviews, yet, it is underused, and GnRH agonists are favored even when Danazol in combination seems more effective. A previously published case report on use of the combination of nandrolone and stanozolol to treat a young woman scheduled for hemicolectomy is discussed as an alternative to surgery along with the limits of standard therapy. This review will focus on recent research and theories seeking to establish causation for disease and offer treatment recommendations. Keywords: Endometriosis; Environmental toxins; Xenoestrogens;
    [Show full text]
  • EUROPEAN PHARMACOPOEIA 10.0 Index 1. General Notices
    EUROPEAN PHARMACOPOEIA 10.0 Index 1. General notices......................................................................... 3 2.2.66. Detection and measurement of radioactivity........... 119 2.1. Apparatus ............................................................................. 15 2.2.7. Optical rotation................................................................ 26 2.1.1. Droppers ........................................................................... 15 2.2.8. Viscosity ............................................................................ 27 2.1.2. Comparative table of porosity of sintered-glass filters.. 15 2.2.9. Capillary viscometer method ......................................... 27 2.1.3. Ultraviolet ray lamps for analytical purposes............... 15 2.3. Identification...................................................................... 129 2.1.4. Sieves ................................................................................. 16 2.3.1. Identification reactions of ions and functional 2.1.5. Tubes for comparative tests ............................................ 17 groups ...................................................................................... 129 2.1.6. Gas detector tubes............................................................ 17 2.3.2. Identification of fatty oils by thin-layer 2.2. Physical and physico-chemical methods.......................... 21 chromatography...................................................................... 132 2.2.1. Clarity and degree of opalescence of
    [Show full text]
  • Metformin Enhances Nomegestrol Acetate Suppressing Growth of Endometrial Cancer Cells and May Correlate to Downregulating Mtor Activity in Vitro and in Vivo
    International Journal of Molecular Sciences Article Metformin Enhances Nomegestrol Acetate Suppressing Growth of Endometrial Cancer Cells and May Correlate to Downregulating mTOR Activity In Vitro and In Vivo Can Cao 1,2, Jie-yun Zhou 2, Shu-wu Xie 2, Xiang-jie Guo 2, Guo-ting Li 2, Yi-juan Gong 2, Wen-jie Yang 2, Zhao Li 2, Rui-hua Zhong 2, Hai-hao Shao 2 and Yan Zhu 2,* 1 Pharmacy School, Fudan University, Shanghai 200032, China 2 Lab of Reproductive Pharmacology, NHC Key Lab of Reproduction Regulation, Shanghai Institute of Planned Parenthood Research, Fudan University, Shanghai 200032, China * Correspondence: [email protected]; Tel.: +86-21-6443-8416 Received: 11 June 2019; Accepted: 3 July 2019; Published: 5 July 2019 Abstract: This study investigated the effect of a novel progestin and its combination with metformin on the growth of endometrial cancer (EC) cells. Inhibitory effects of four progestins, including nomegestrol acetate (NOMAC), medroxyprogesterone acetate, levonorgestrel, and cyproterone acetate, were evaluated in RL95-2, HEC-1A, and KLE cells using cell counting kit-8 assay. Flow cytometry was performed to detect cell cycle and apoptosis. The activity of Akt (protein kinase B), mTOR (mammalian target of rapamycin) and its downstream substrates 4EBP1 (4E-binding protein 1) and eIF4G (Eukaryotic translation initiation factor 4G) were assayed by Western blotting. Nude mice were used to assess antitumor effects in vivo. NOMAC inhibited the growth of RL95-2 and HEC-1A cells, accompanied by arresting the cell cycle at G0/G1 phase, inducing apoptosis, and markedly down-regulating the level of phosphorylated mTOR/4EBP1/eIF4G in both cell lines (p < 0.05).
    [Show full text]
  • KLBD Kosher Certified Retail Products List
    KLBD Kosher Certified Retail Products List Section 1 Food Categories and Company Contact Details Section 2 Full Product List As the kosher statuses are subject to change, please request an up-to-date kosher certificate directly from the manufacturer or supplier. Tel: + 44 (0) 20 8343 6255 www.klbdkosher.org Sign up to the KLBD New Products Newsletter @KLBDkosher COMPANY INDEX AND CONTACT INFO Go to Home Go to Products Category Company Website Phone Email Name Country Sold Aluminum Trays Nicholl Food Packaging + 44 (0) 1543 460400 UK Baked Goods Green Isle Foods Ltd www.northernfoods.co m +353 433 340 800 UK Baked Goods The Family Bread www.thefamilybread.co. Limited uk +44 (0) 20 3372 4737 Baking Supplies GB Ingredients Ltd www.lallemand.com +44 (0) 1394 606 400 UK Baking Supplies Knightsbridge PME www.cakedecoration.co. uk +44 (0) 20 3234 0049 UK Cereals Dorset Cereals Limited www.dorsetcereals.co.u k +44 (0) 1305 751000 UK Cereals Scrumshus Granola Limited www.scrumshus.co.uk +44 (0) 20 8455 8557 UK Cereals SuperLife Ltd www.superlife.ie +353 86 256 7993 [email protected] UK Cereals Weetabix Ltd www.weetabix.co.uk +44 (0) 1536 722 181 UK and Israel Cheese Charedi Dairies +44 (0) 20 8800 5766 UK Cheese Schwartz S Ltd Chips McCain Foods (GB) Limited www.mccain.com +44 (0) 1723 584141 UK Organic Seed & Bean www.seedandbean.co.u Chocolates Company Limited k +44 (0) 20 8343 5420 UK Cider & Perry H. Weston & Sons www.westons- Limited cider.co.uk +44 (0) 1531 660 233 UK Cleaning Materials The London Oil Refining www.astonishcleaners.c
    [Show full text]